International pharmaceutical social risk regulation: An ethical perspective

被引:1
|
作者
Gordon, Cameron [1 ]
机构
[1] Univ Canberra, Fac Business & Govt, Bruce, ACT 2601, Australia
关键词
risk; externality; pharmaceutical industry; drug regulation; social risk; drug policy; ethics; corporate social responsibility;
D O I
10.2478/v10007-011-0010-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmaceutical production and distribution constitute big business. For the companies the rewards can be substantial. Rates of return on drug company investments tend to be higher than many other manufacturing enterprises. But reward is only one side of the story. There is also the issue of social risk, the focus of this article. Social risk for pharmaceutical production is especially pronounced. An ineffective or, worse, dangerous drug, can have dire consequences for the population at large. For this reason, there is elaborate government regulation and oversight of drug safety and risk. These systems, especially in the US and Europe, will be the main focus of this paper. The two systems will be described, and then compared and contrasted in terms of their framing of social risk and actions governments take to limit it. Systems elsewhere, especially in the developing world, are increasing in relative importance and these will be briefly discussed as well. Ethical issues that have arisen in these various systems will be surfaced and analysed. The paper will close with some conclusions and suggestions for further research.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 50 条
  • [21] Social Work in a Digital Age: Ethical and Risk Management Challenges
    Reamer, Frederic G.
    SOCIAL WORK, 2013, 58 (02) : 163 - 172
  • [22] The nexus between ethical corporate marketing, ethical corporate identity and corporate social responsibility An internal organisational perspective
    Powell, Shaun M.
    EUROPEAN JOURNAL OF MARKETING, 2011, 45 (9-10) : 1365 - 1379
  • [23] Risk, Overdiagnosis and Ethical Justifications
    Rogers, Wendy A.
    Entwistle, Vikki A.
    Carter, Stacy M.
    HEALTH CARE ANALYSIS, 2019, 27 (04) : 231 - 248
  • [24] Risk, Overdiagnosis and Ethical Justifications
    Wendy A. Rogers
    Vikki A. Entwistle
    Stacy M. Carter
    Health Care Analysis, 2019, 27 : 231 - 248
  • [25] Ethical issues in the biotechnology and pharmaceutical industries
    Aronson, D
    Best, SG
    Werner, MJ
    Moos, WH
    DRUG DEVELOPMENT RESEARCH, 2004, 63 (03) : 89 - 92
  • [26] Impacts of Corporate Social Responsibility on Employees' Mental Fatigue: Employees' Ethical Perspective
    Zheng, Linlin
    Li, Wenzhuo
    Addis, Amsalu K.
    Ye, Di
    Dong, Yashi
    FRONTIERS IN PSYCHOLOGY, 2022, 13
  • [27] Ethical values and social care robots for older people: an international qualitative study
    Heather Draper
    Tom Sorell
    Ethics and Information Technology, 2017, 19 : 49 - 68
  • [28] Ethical values and social care robots for older people: an international qualitative study
    Draper, Heather
    Sorell, Tom
    ETHICS AND INFORMATION TECHNOLOGY, 2017, 19 (01) : 49 - 68
  • [29] GAMES OF CHANCE REGULATION IN CROATIA AS A SOCIAL RISK
    Ricijas, Neven
    Maglica, Toni
    Hundric, Dora Dodig
    LJETOPIS SOCIJALNOG RADA, 2019, 26 (03): : 335 - 361
  • [30] SOCIAL RESPONSIBILITYAND ETHICAL BEHAVIOR: STUDY ON COMPANIES WITH SOCIAL POWER
    Veres, Vincentiu
    Mortan, Maria
    Marin, Anamaria
    CRISES AFTER THE CRISIS: INQUIRIES FROM A NATIONAL, EUROPEAN AND GLOBAL PERSPECTIVE, VOL II, 2011, : 456 - 465